To study the mechanism of panax notoginseng in the treatment of aspirin resistance in the secondary prevention of stroke based on TLR4/MyD88/NF-?B signaling pathway

Xi'an Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1.Agree to participate in this clinical trial and sign the informed consent;
•2.Aged < 65 years, gender unlimited, taking single antiplatelet drug;
•3.Essen Stroke Risk Scale score <= 3 points;
•4.The traditional Chinese medicine with the effect of promoting blood circulation and removing blood stasis should not be used overlapped in the observation period.

•1.Patients with transient ischemic attack and cerebral infarction requiring double antibody;
•2.Patients with cerebral hemorrhage after cerebral infarction, cerebral arteritis, brain tumor, brain trauma, cerebral parasitic disease, rheumatic heart disease;
•3.Patients with bleeding tendency or severe bleeding within 3 months;
•4.Severe hepatic and renal hematopoiesis and metabolic system diseases;
•5.Legal disabled patients (blind, deaf, dumb, intellectual, mental and other physical disabilities caused by other reasons), affecting the evaluation of neurological function defects;
•6.Suspected or present a history of alcohol and drug abuse, or other conditions that, in the investigator's judgment, reduce or complicate the likelihood of inclusion;
•7.Participating in other clinical trials or participating in clinical trials of other drugs for less than 3 months.

发起方

Xi'an Hospital of Traditional Chinese Medicine